Cardiovascular and Metabolic Market Forecast

Datamonitor expects antidiabetic therapies to emerge as the biggest revenue earner in the cardiovascular and metabolic markets by 2019, with growth driven by a rich pipeline and new drug classes. Thrombosis has stable sales; however, the heavy genericization of the hypertension and dyslipidemia primary care markets will lead to the overall market decreasing by -0.5% in the seven major markets.

The Drug Discovery Outsourcing Market

This report investigates current trends and opportunities affecting decisions on whether or not to outsource drug discovery. Outsourcing to low cost offshore destinations such as China and India are examined in detail. The report also covers a variety of strategic collaborations, academic partnerships and outsourcing opportunities along with case studies. 

COMPARATIVE MARKET RESEARCH OF NORMAL TOOTH PASTE VS HERBAL TOOTH PASTE FROM UJJAIN CITY OF MADHYA PRADESH

The present paper through the light on the comparative marketing survey of normal and herbal tooth paste from the selected area of Ujjain city of Madhya Pradesh, India. Market research was carried in April 2011; data’s were collected from 5, general shop, 5 Doctors and 5 chemist of Ujjain city.  Results showed that the sale of normal tooth paste is higher than the herbal tooth paste due to several factors and some marketing strategies.

Full 4 pages Report is available for download at Downloads.

Future Directions in Regenerative Medicine

This report covers the development of therapies to replace human cells or promote their regeneration: including cell therapies, tissue engineering, drugs, and medical devices. Each company profiled has at least one project in preclinical or Phase I study. Many also have later stage or launched products, which are covered briefly to illustrate the potential of the next generation of candidates.

Pharmaceutical Key Trends 2011 – Biosimilar Market Overview

In 2009, the combined biosimilars market size for the US and five major European markets was $150m. With more than 30 branded biologics with sales of $51bn set to lose patent exclusivity between 2011 and 2015, Datamonitor forecasts that the global biosimilar market will grow from $243m in 2010 to $3.7bn in 2015.

Building Biotech Technology Transfer Opportunities

Technology transfer, particularly of new biotechnologies that offer novel means to address unmet medical needs, can effectively address many R&D challenges. They also provide technology developers with a way of monetizing inventions. This report analyzes how to avoid pitfalls in the management of biotech tech transfer projects and uses detailed case studies to illustrate best practices. rbhc0257

The Digitized Medical Image Archiving Outlook to 2015

Over the next decade, as the output from imaging modalities increases in resolution quality, there will be a greater requirement storage space for digital images. This report analyzes the requirement of digital storage space for archived medical images up to 2015 for the following countries: the US, Canada, the UK, France, Germany, Spain, Italy, Scandinavia, Benelux, and Japan.

Innovative Drug Discovery in Emerging Markets

Emerging markets have represented important growth opportunities for the global pharmaceutical industry, but it has been unclear the extent to which this has been accompanied by growth in domestic innovation within these countries. This report examines the most prominent domestic innovators, assessing key research strategies, front-running candidates, scientific strengths, and patent portfolios.

U.S. Biopharmaceutical Market - Trends, Forecast, Competition & Strategic Analysis (2009 - 2016)

The U.S. biopharmaceuticals market is expected to increase to $144 billion by 2016. The growth is expected as a result of the launch of new products, approval of new indications for existing therapies and drugs, and increase in population aged 65 years and above. From 2009 to 2016 the U.S. market revenues are forecasted to grow at a compound annual growth rate (CAGR) of 11.2%.

Top 10 Drug Discovery Technologies - Strategic Analysis and Global Forecasts (2010 to 2015)

The top 10 drug discovery technologies play a vital role in the growth of the entire pharmaceutical industry as they are the key contributors in the swift introduction of blockbusters and innovative drugs, which is the most important aspect for the pharmaceutical companies. The applications of these technologies in the introduction of drugs for diverse diseases such as cancer, CVD, CNS disorders such as Parkinson's and Alzheimer's and other serious chronic diseases have created significant opportunities for the market growth in the future. The slow growth of the introduction of new blockbuster drugs is a major concern which the drug development companies are catering to by using these top technologies.

Monoclonal antibodies: 2009 update

The report provides a comprehensive financial and strategic analysis of the mAb market, forecasting its commercial evolution out to 2014 and assessing trends by product, company, therapy area, geography, technology and target type. It also provides an insight into the direction of mAb technology evolution and an analysis of pipeline dynamics.

Hormonal Replacement Therapy for Menopausal Symptoms - Safety fears continue to haunt the market

Sales of hormone replacement therapies treating menopausal symptoms have seen a sharp decline in recent years as a result of safety concerns raised by the Women's Health Initiative (WHI) study in 2002. Coupling this with Pfizer's acquisition of Wyeth, the leading estrogen manufacturer, the future direction of the market is uncertain.

Sexual Dysfunction - The quest for the new Viagra continues

Drug developers interested on the sexual dysfunction market are searching for the next Viagra. Companies are focusing on premature ejaculation and female hypoactive sexual desire disorder, which are suggested to be as prevalent as erectile dysfunction. As products advance through the pipeline, there are several challenges that will have to be addressed in order to succeed in these markets.

Diabetes market growth driven by epidemiological trends and rich pipeline

Datamonitor expects the antidiabetics market to grow to $34.8 billion in 2019 for the seven major markets. Januvia will become the leading franchise from 2012 after patent expiry of Actos, with franchise sales reaching nearly $6 billion by 2019. Pipeline candidates will make up 30% of sales in 2019, with once-weekly GLP-1 agonists and new long-acting insulin analogs meeting success.

Strategies for Managing Pharmaceutical Workforce and Site Reductions: Analysis of legal, productivity, and quality control issues

This report examines the different strategies available for managing the layoffs and site closures resulting from not only the outsourcing of R&D and manufacturing, but also the transition from small-molecules to biologics and the need to exploit new markets. Case studies from the pharmaceutical industry are provided to highlight pitfalls and illustrate best practice.

Pharmaceutical M&A in the Asia-Pacific Region - India and China drive regional activity but Japan still dominates high value transactions

Expanding healthcare coverage in emerging Asia-Pacific markets, rapid economic growth and burgeoning middle classes are attracting foreign M&A as companies attempt to offset future losses from the looming threat of the 2011 "patent cliff" and slowing growth in major developed markets. As these markets develop, consolidation of the domestic industry is also driving M&A in the Asia-Pacific region.

Pharmaceutical Company Outlook to 2014

PharmaVitae universe Rx sales are forecast to expand at a 2008-14 CAGR of 1.2%, down 9.3 percentage points from 2002-08. The underlying cause of this falling rate is the much-discussed genericization of small molecule products. However, not all sectors are equally exposed, prompting a shake-up of the industry and an increasing pursuit of cost savings to sustain operating profit growth rates.

Innovations and Opportunities in Therapeutic Vaccines: Technology platforms, key players, and early pipeline candidates

This report explains what therapeutic vaccines are, how they work, and why drug developers around the world are using this approach to address everything from allergies to literally every kind of cancer. More than 70 new proprietary technologies are named and explained, with details of licensing deals and intellectual property positions.